Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (31-40 of 350) with videos related to

Pageof 35
Sort By:
Sangre|February 1, 1989
Biological molecules in the treatment of hematological disordersR Kurzrock, M Talpaz, U Gutterman
Seminars in Hematology|April 1, 1995
The natural history of chronic myelogenous leukemia in the interferon eraS Giralt, H Kantarjian, M Talpaz
Cancer Treatment and Research|January 1, 1995
Interleukin-1 and its inhibitors: implications for disease biology and therapyZ Estrov, R Kurzrock, M Talpaz
Current Treatment Options in Oncology|June 12, 2002
Chronic myelogenous leukemia in chronic phaseR Kurzrock, H Kantarjian, M Talpaz
JAMA|August 31, 2001
Chronic myelogenous leukemiaM Kalidas, H Kantarjian, M Talpaz
Leukemia & Lymphoma|October 1, 1996
Practical guidelines for the management of chronic myelogenous leukemia with interferon alphaS O'Brien, H Kantarjian, M Talpaz
Harefuah|June 15, 1979
[Thrombosis of the subclavian and innominate veins three years before the appearance of lung cancer]A Schattner, M Talpaz, A Eliraz
Oncology (Williston Park, N.Y.)|September 1, 1987
Biologic therapy of chronic myelogenous leukemiaH M Kantarjian, M Talpaz, J Gutterman
Cancer Immunology, Immunotherapy : CII|January 1, 1982
Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remissionM Talpaz, M Bielski, E M Hersh
Leukemia|January 1, 1997
Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-upJ F Seymour, M Talpaz, R Kurzrock
Pageof 35

Showing results (31-40 of 350) with videos related to

Sort By:
Pageof 35
Sangre|February 1, 1989
Biological molecules in the treatment of hematological disordersR Kurzrock, M Talpaz, U Gutterman
Seminars in Hematology|April 1, 1995
The natural history of chronic myelogenous leukemia in the interferon eraS Giralt, H Kantarjian, M Talpaz
Cancer Treatment and Research|January 1, 1995
Interleukin-1 and its inhibitors: implications for disease biology and therapyZ Estrov, R Kurzrock, M Talpaz
Current Treatment Options in Oncology|June 12, 2002
Chronic myelogenous leukemia in chronic phaseR Kurzrock, H Kantarjian, M Talpaz
JAMA|August 31, 2001
Chronic myelogenous leukemiaM Kalidas, H Kantarjian, M Talpaz
Leukemia & Lymphoma|October 1, 1996
Practical guidelines for the management of chronic myelogenous leukemia with interferon alphaS O'Brien, H Kantarjian, M Talpaz
Harefuah|June 15, 1979
[Thrombosis of the subclavian and innominate veins three years before the appearance of lung cancer]A Schattner, M Talpaz, A Eliraz
Oncology (Williston Park, N.Y.)|September 1, 1987
Biologic therapy of chronic myelogenous leukemiaH M Kantarjian, M Talpaz, J Gutterman
Cancer Immunology, Immunotherapy : CII|January 1, 1982
Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remissionM Talpaz, M Bielski, E M Hersh
Leukemia|January 1, 1997
Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-upJ F Seymour, M Talpaz, R Kurzrock
Pageof 35